[144] Dyne Therapeutics, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Dyne Therapeutics, Inc. (DYN). The filing indicates a neutral impact and sentiment, detailing the proposed sale of common stock by an individual, acquired through a private placement from the issuer in December 2022. The filing specifies Merrill Lynch as the broker for the sale of 127,182 shares with an aggregate market value of $2,934,088.74.
Will Barry Greene’s Board Role Shape Dyne Therapeutics’ (DYN) Path From Platform to Products?
Dyne Therapeutics has appointed veteran biopharma executive Barry E. Greene to its Board, a move expected to strengthen its commercialization and rare disease expertise. Greene's experience in guiding therapies from development to commercialization in various disease areas could influence Dyne's strategy for its FORCE platform programs. While his appointment may not immediately impact near-term clinical and regulatory milestones, it increases confidence in the company's execution as it advances toward product approvals amid risks like funding needs, trial setbacks, and regulatory uncertainty.
Dyne Therapeutics Inc (DYN) Stock Price | Analyst Target 40.13 & Strong Buy Consensus
Analysts have set a strong buy consensus and a price target of $40.13 for Dyne Therapeutics Inc (DYN). The stock is currently trading at $23.07, reflecting an increase of 5.87% in the last 24 hours. Dyne Therapeutics, a biotechnology company, focuses on developing therapies for severe muscle diseases and currently has a market capitalization of $3.81 billion.
Price to book forward of Dyne Therapeutics, Inc. – NASDAQ:DYN
This article displays the "Price to book forward" metric for Dyne Therapeutics, Inc. (NASDAQ: DYN) on TradingView. It provides a quick financial overview for the company, accessible through the platform's various financial analysis tools. The page highlights that the market is currently closed with no trades.
Dyne therapeutics director Jason Rhodes sells $10.7m in stock
Jason P Rhodes, a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), sold over 504,000 shares of the company's common stock for approximately $10.7 million across two transactions in late June 2026, executed via a Rule 10b5-1 trading plan. Despite the sale, the stock has shown a significant 133% return over the past year, though InvestingPro analysis suggests it is currently overvalued. The company recently expanded its debt facility and completed enrollment for a key clinical trial, while also appointing a new board member.
Form 4 Dyne Therapeutics Inc For: 30 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Dyne Therapeutics Inc. for the period ending June 30. It includes the company's stock symbol DYN, which saw a 4.47% increase, and is dated June 30, 2026, at 07:14 p.m.
Atlas funds linked to Dyne (DYN) director sell 504,695 shares
Funds associated with Dyne Therapeutics director Jason P. Rhodes sold 504,695 shares of common stock in open-market transactions on June 26 and June 29, 2026. The sales were executed through Atlas Venture funds at weighted-average prices between $21.14 and $21.28, under a pre-established Rule 10b5-1 trading plan. Despite these sales, Atlas-affiliated entities still hold significant indirect stakes in Dyne Therapeutics.
Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma
DelveInsight's report highlights that over 20 companies are actively developing more than 22 Myotonic Dystrophy therapies, covering various clinical development stages from pre-clinical to marketed phases. Key emerging therapies include EF-210, ARO-DM1, VX-670, PGN-EDODM1, and DYNE-101, with Dyne Therapeutics' zeleciment basivarsen (DYNE-101) aiming for a U.S. launch by mid-2028 following positive trial results and FDA Breakthrough Therapy Designation. The report also details recent clinical trial updates, such as a partial FDA clinical hold on PepGen's FREEDOM2-DM1 trial and Avidity Biosciences' delpacibart etedesiran receiving Orphan Drug Designation in Japan.
Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma
DelveInsight's "Myotonic Dystrophy Pipeline 2026" report evaluates over 20 companies developing more than 22 treatment therapies for Myotonic Dystrophy, covering clinical trials, mechanisms of action, and routes of administration. The report highlights key emerging therapies like DYNE-101 from Dyne Therapeutics, which recently completed enrollment for a registrational expansion cohort and received Breakthrough Therapy Designation. It also notes regulatory developments such as a partial clinical hold on PepGen's PGN-EDODM1 trial and Avidity Biosciences' delpacibart etedesiran findings being published in The New England Journal of Medicine, alongside its Orphan Drug Designation in Japan.
Dyne Therapeutics, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Dyne Therapeutics, Inc. (DYN) on June 29, 2026. The filing indicates a proposed sale of securities, specifically 40,702 shares of common stock acquired via private placement in 2020 by the issuer, with Merrill Lynch as the broker. The aggregate market value of the shares to be sold is $852,299.88.
Dyne therapeutics director Jason P Rhodes sells $5.65m in stock
Jason P Rhodes, a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), recently sold 267,760 shares of the company’s common stock for approximately $5.65 million through a Rule 10b5-1 trading plan. These transactions took place between June 23 and June 25, 2026, with prices ranging from $21.00 to $21.50 per share. The sales follow a significant 105% return for Dyne Therapeutics over the past year, while the stock is currently trading near its Fair Value.
Price to earnings forward of Dyne Therapeutics Inc – BX:DYN
This page provides financial data specifically on the "Price to earnings forward" for Dyne Therapeutics Inc (BX:DYN). The content indicates the market is closed, with no current trades. It also highlights that financial and reference data are provided by ICE Data Services and FactSet Research Systems Inc., respectively.
Price to sales forward of Dyne Therapeutics, Inc. – NASDAQ:DYN
This article provides the "Price to sales forward" financial metric for Dyne Therapeutics, Inc. (NASDAQ: DYN). It indicates that the period value is available and notes that the market was closed at the time of publication, showing no trades.
Enterprise value to EBIT forward of Dyne Therapeutics Inc – BX:DYN
This article provides forward-looking enterprise value to EBIT data for Dyne Therapeutics Inc (BX:DYN) on TradingView. It appears to be a financial data snippet from a larger platform, showing market status and financial figures.
Dyne Therapeutics stock initiated at buy by TD Cowen on platform
TD Cowen has initiated coverage on Dyne Therapeutics Inc. (NASDAQ:DYN) with a "buy" rating, citing the company's FORCE platform and late-stage clinical programs for neuromuscular and CNS diseases. The stock has seen a significant surge of 105% over the past year, reflecting investor optimism. Dyne Therapeutics is advancing z-rostudirsen for DMD and z-basivarsen for DM1, with a biologics license application submitted for the former and data for the latter expected by Q1 2027.
Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes
Dyne Therapeutics' CFO, Lucera Erick, sold 2,362 shares of common stock at a weighted average price of $20.37 per share. This transaction was conducted to meet tax obligations arising from the vesting and settlement of restricted stock units. Following the sale, Erick retains beneficial ownership of 121,563 shares, including 110,513 unvested restricted stock units, linking a significant portion of his compensation to the company's future performance.
Dyne Therapeutics(DYN.US) Director Sells US$5.65 Million in Common Stock
Dyne Therapeutics (DYN.US) Director, HOLLAND TIMOTHY, sold 160,000 shares of common stock at an average price of $35.33 per share, totaling $5.65 million. This transaction was reported on June 25, 2026.
Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares
Funds affiliated with Dyne Therapeutics (DYN) director Jason P. Rhodes sold a total of 267,760 shares of common stock between June 23 and June 25, 2026. These open-market sales were executed at weighted average prices around $21 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026. Rhodes disclaims direct beneficial ownership, stating the shares are held indirectly through various Atlas Venture entities.
Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com
Investing.com reports on a Form 4 filing for Dyne Therapeutics Inc. which occurred on June 26. This brief article primarily serves as an announcement for the regulatory filing related to the company. The specific details of the Form 4 are not provided within the article text.
Dyne Therapeutics Inc Actuals & Estimates (NASDAQ:DYN)
This article provides an overview of Dyne Therapeutics Inc. (NASDAQ: DYN), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report, and recent earnings and revenue figures.
Form 4 Dyne Therapeutics Inc For: 24 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Dyne Therapeutics Inc. dated June 24. It provides no further details on the filing but includes stock market performance data for Dyne Therapeutics (DYN) and various indices and commodities. The article appears to be a stub or a placeholder for more detailed insider transaction news.
DYN Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Dyne Therapeutics, Inc. (DYN) stock, based on analyst opinions. It details the current stock price, historical performance, earnings information, and financial data for DYN, along with answers to frequently asked questions about the company's stock.
Dyne Therapeutics (DYN) Adds Barry Greene And Expands Funding, Is The Stock Still A Bargain?
Dyne Therapeutics (DYN) recently appointed Barry E. Greene to its board and expanded its loan facility, prompting a re-evaluation of its stock. Despite significant one-year returns, an SWS DCF model suggests Dyne is significantly undervalued at $20.33 per share, estimating a fair value of $97.89, though the company remains unprofitable and subject to clinical risks. While its P/B ratio is above the industry average, it's below peers, indicating mixed market signals.
Dyne Therapeutics (DYN) Adds Barry Greene And Expands Funding, Is The Stock Still A Bargain?
Dyne Therapeutics (DYN) has appointed Barry E. Greene to its board and expanded its loan facility, prompting a re-evaluation of its stock. The SWS DCF model suggests the stock is significantly undervalued at $20.33 compared to a fair value of $97.89, despite the company still being unprofitable. However, its P/B ratio at 3.9x is above the industry average but below some peers, indicating mixed market signals for this clinical-stage biotech.
Dyne Therapeutics (DYN) director-affiliated fund sells 263,962 shares under 10b5-1 plan
An entity affiliated with Dyne Therapeutics director Dirk Kersten, ForDyne B.V., sold 263,962 shares of DYN common stock in open-market transactions on June 22–23, 2026. The sales, executed under a pre-arranged Rule 10b5-1 trading plan from November 2025, were priced around $20–$21 per share. Following these transactions, ForDyne B.V. still holds a significant stake of 3,848,256 shares, indicating routine portfolio management rather than a change in insider alignment.
Dyne Therapeutics (DYN) Expands Term Loan Facility with Hercules Capital by $400M to Advance Clinical Pipeline
Dyne Therapeutics (DYN) has expanded its senior secured term loan facility with Hercules Capital to up to $400 million, including an immediate $50 million funding and additional tranches tied to clinical and regulatory milestones. These funds will support lead candidates for Duchenne muscular dystrophy and myotonic dystrophy type 1, strengthening Dyne's financial position ahead of potential US commercial launches. The agreement provides non-dilutive capital and reflects continued support for Dyne's progress in developing treatments for rare neuromuscular diseases.
Dyne Therapeutics (DYN) Is Up 12.1% After Expanding Debt Facility And Adding Veteran Biotech Director
Dyne Therapeutics has expanded its debt facility to US$400 million and appointed veteran biotech executive Barry E. Greene as an independent director. These moves signal the company is building financial and leadership infrastructure for a potential shift towards product launches from clinical development. While the expanded debt offers non-dilutive funding, investors should be aware of the increased secured debt on an unprofitable balance sheet if milestones are not met.
[144] Dyne Therapeutics, Inc. SEC Filing
This SEC filing (Form 144) for Dyne Therapeutics, Inc. (DYN) indicates a proposed sale of securities. The document details the filer and issuer information, including the class of securities to be sold (Common Stock), the number of shares and their aggregate market value, and the acquisition details of these securities from a private placement in December 2022. It also includes contact information and a required representation from the seller regarding material adverse information about the issuer.
Dyne Therapeutics Appoints Barry Greene to Board of Directors
Dyne Therapeutics has appointed Barry Greene to its Board of Directors, bringing over three decades of biopharmaceutical industry experience. His expertise in building and scaling innovative companies, particularly in rare diseases, will be crucial as Dyne aims to transition into a commercial biotechnology company with anticipated product launches. Greene's appointment is expected to help the company maximize patient and shareholder value and strengthen its leadership for future growth.
Director at Dyne Therapeutics (DYN) awarded 57,463 stock options vesting over 3 years
Dyne Therapeutics director Barry E. Greene was granted 57,463 stock options on June 22, 2026, with an exercise price of $20.87 per share and an expiration date of June 21, 2036. The options will vest in equal monthly installments over three years, concluding on June 22, 2029, representing an equity compensation award rather than a market transaction. This grant is detailed in a recent SEC Form 4 filing.
Dyne Therapeutics (NASDAQ: DYN) director Barry Greene files initial Form 3
Dyne Therapeutics (NASDAQ: DYN) director Barry E. Greene has filed an initial Form 3 ownership report, indicating his position as a director without any reported transactions or derivative positions. This filing serves as an initial disclosure of beneficial ownership. The Form 3 shows zero buy or sell transactions and no derivative securities, establishing a neutral net share change for Greene's initial reporting.
Dyne Therapeutics appoints Barry Greene to board of directors By Investing.com
Dyne Therapeutics has appointed Barry Greene to its board of directors, leveraging his 30 years of biopharmaceutical industry experience, including leadership roles at Sage Therapeutics and Alnylam Pharmaceuticals. This appointment coincides with Dyne's stock surging 92% and the company maintaining a strong financial position as it advances clinical programs for neuromuscular diseases and prepares for potential product launches. Dyne Therapeutics is also progressing with its Duchenne muscular dystrophy and myotonic dystrophy type 1 programs, securing additional funding, and aiming for accelerated approval of a new treatment.
Dyne Therapeutics elects Barry E. Greene to Board as Class I director
Dyne Therapeutics has announced the election of Barry E. Greene as a Class I director to its board, effective June 22, 2026. This appointment was a recommendation from the Nominating and Corporate Governance Committee, and Mr. Greene has been determined to be independent under Nasdaq rules, although not appointed to any specific committees. The information is based on an SEC filing from Dyne Therapeutics.
Barry Greene joins Dyne Therapeutics (DYN) board with new option grant
Dyne Therapeutics has appointed Barry E. Greene to its Board of Directors as an independent Class I director, with his term extending until the 2027 annual meeting. Upon joining, Greene received a stock option for 57,463 shares at an exercise price of $20.87 per share, vesting monthly over three years, which will fully accelerate upon a change in control. He will also receive an annual cash compensation of $45,000, additional annual equity grants, and reimbursement for expenses associated with Board meetings.
Dyne Therapeutics appoints Barry Greene to board of directors
Dyne Therapeutics (NASDAQ:DYN) has appointed Barry Greene, a veteran of the biopharmaceutical industry with over 30 years of experience, to its board of directors. Greene's appointment comes as Dyne's stock has surged, reflecting optimism about the company's financial health and pipeline. He previously served as CEO of Sage Therapeutics and held significant roles at Alnylam Pharmaceuticals and Millennium Pharmaceuticals.
Entity tied to Dyne (DYN) director sells 84K pre-planned shares
An entity associated with Dyne Therapeutics (DYN) director Dirk Kersten, ForDyne B.V., sold 84,355 common shares in pre-planned transactions on June 17 and 18, 2026. The shares were sold at an approximate weighted average price of $20 per share under a Rule 10b5-1 trading plan. After these sales, ForDyne B.V. indirectly held 4,112,218 shares of Dyne Therapeutics common stock.
Dyne Therapeutics Appoints Barry Greene to Board of Directors
Dyne Therapeutics has appointed Barry Greene to its Board of Directors, a strategic move as the company anticipates transforming into a commercial biotechnology entity. Greene brings over three decades of biopharmaceutical experience, including leadership roles at Sage Therapeutics and Alnylam Pharmaceuticals, and will contribute his expertise in building and scaling innovative companies, particularly in rare diseases. His appointment is expected to help Dyne maximize patient and shareholder value as it advances its clinical programs and prepares for potential product launches.
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
Dyne Therapeutics has expanded its debt facility with Hercules Capital, Inc. to up to $400 million, securing an additional $125 million in borrowing capacity. This move strengthens Dyne's financial position as it advances clinical programs for Duchenne muscular dystrophy and myotonic dystrophy type 1, with $50 million funded immediately upon the amendment. The company aims to prepare for potential U.S. launches of zeleciment rostudirsen and zeleciment basivarsen in the next two years.
Dyne Therapeutics (DYN) RBC Capital Markets Global Healthcare Conference 2026 summary
This summary of Dyne Therapeutics' (DYN) presentation at the RBC Capital Markets Global Healthcare Conference 2026 highlights the company's focus on execution and commercial launch preparations for DMD and DM1 therapies. Key points include the advanced regulatory strategies for its lead products, including Breakthrough Therapy designation and an on-track BLA submission for DMD, and the strong commercialization plans leveraging established pricing and patient advocacy. The company's FORCE platform continues to drive a deep pipeline and market expansion opportunities for additional exon targets.
Dyne Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
Dyne Therapeutics (Nasdaq: DYN) has granted inducement equity awards to 6 new employees, consisting of non-statutory stock options for 126,000 shares and restricted stock units for 40,100 shares. These awards were made in accordance with Nasdaq Listing Rule 5635(4) to induce their acceptance of employment. The grants are subject to vesting schedules over four years and are governed by the company's 2024 Inducement Stock Incentive Plan.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics, Inc. announced that it has granted inducement equity awards to six new employees, as per Nasdaq Listing Rule 5635(c)(4). These awards include non-statutory stock options for 126,000 shares and restricted stock units for 40,100 shares, both vesting over four years. This initiative is part of the company's focus on developing treatments for genetically driven neuromuscular diseases.
Dyne awards stock options, RSUs to 6 newly hired employees
Dyne Therapeutics (Nasdaq: DYN) has granted inducement equity awards to six new employees, consisting of non-statutory stock options for up to 126,000 shares and 40,100 restricted stock units (RSUs). These awards, made under Nasdaq Listing Rule 5635(c)(4) and Dyne’s 2024 Inducement Stock Incentive Plan, are designed to attract and retain talent. Both the stock options and RSUs will vest over four years, subject to continuous employment.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics, Inc. announced it has granted inducement equity awards to six newly hired employees. These awards, consisting of non-statutory stock options for 126,000 shares and restricted stock units for 40,100 shares, were made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for their employment. The grants are part of the company's efforts to develop therapies for genetically driven neuromuscular diseases.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics has granted inducement equity awards to six new employees in accordance with Nasdaq Listing Rule 5635(c)(4). These awards include non-statutory stock options for up to 126,000 shares and restricted stock units for 40,100 shares, vesting over four years. This initiative aims to align new talent with the company's mission to develop therapies for genetically driven neuromuscular diseases.
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
Dyne Therapeutics has expanded its non-dilutive senior secured term loan facility with Hercules Capital, Inc. to up to $400 million, securing an additional $125 million in borrowing capacity. This amendment includes an immediate $50 million funding, strengthening Dyne's balance sheet as it advances clinical programs for rare neuromuscular diseases. The additional capital will support the company's preparation for potential U.S. launches of zeleciment rostudirsen and zeleciment basivarsen in the next two years.
Dyne therapeutics CEO John Cox sells $49,179 in stock
John Cox, CEO and President of Dyne Therapeutics, Inc., sold 2,683 shares of company stock worth $49,179 on June 16, 2026, to cover tax withholding obligations linked to restricted stock unit vesting. This automatic sale was planned under a Rule 10b5-1 trading plan and not a discretionary trade. Following the transaction, Cox still holds a significant amount of Dyne Therapeutics stock, both directly and indirectly.
Dyne Therapeutics (DYN) CMO auto-sells shares to cover tax withholding
Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, automatically sold 887 shares of common stock at a weighted average price of $18.33 per share. This sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units granted on December 4, 2024, under a Rule 10b5-1 plan. Following this transaction, Kerr holds 169,155 shares, which includes 145,313 unvested restricted stock units.
ForDyne B.V. (DYN) reports multiple April 2026 resale lots totaling millions
ForDyne B.V. (DYN) has filed a Form 144, disclosing proposed sales of Common Stock across multiple dates in April 2026. The filing details several specific share lots and their corresponding gross proceeds, with the largest single lot on April 17, 2026, comprising 211,974 shares valued at over $4.3 million. The document also indicates an "IPO Conversion of Shares" from September 17, 2020, as the origin of these securities, with UBS Financial Services identified as the broker.
Dyne Therapeutics Inc (DYN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Dyne Therapeutics Inc (DYN), focusing on key metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these valuation ratios have not yet been disclosed by the company. The stock closed at $19.20, up 6.25%, with a market cap of $3.17 billion.
Dyne Therapeutics Expands Hercules Loan Facility to $400 Million, Draws $50 Million Tranche
Dyne Therapeutics has amended its loan agreement with Hercules Capital, increasing the debt facility to up to $400 million and loosening a minimum cash covenant. The company immediately drew $50 million, bringing its outstanding principal to $200 million. The expanded facility, maturing in July 2030, provides Dyne with additional liquidity to support its development milestones.
